R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models
| Autor: | Yann Grobs, Olivier Boucherat, Sandra Breuils-Bonnet, Steeve Provencher, François Potus, Charlotte Romanet, Charifa Awada, Sandra Martineau, Wen-Hui Wu, Eve Tremblay, Karima Habbout, Sébastien Bonnet, Roxane Paulin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pulmonary Arterial Hypertension business.industry Hypertension Pulmonary Conflict of interest Disease Pulmonary Artery Bioinformatics medicine.disease Pulmonary hypertension Vascular remodelling in the embryo Dasatinib Disease Models Animal Smooth muscle Crizotinib Nothing Models Animal (R)-crizotinib Medicine Animals business medicine.drug |
| Zdroj: | The European respiratory journal. 57(5) |
| ISSN: | 1399-3003 |
| Popis: | Pulmonary hypertension (PH) is a life-threatening disease of multiple etiologies. Regardless of the underlying cause, PH is characterised by vasoconstriction and progressive thickening of the pulmonary vessel wall all of which is initiated by the loss of pulmonary artery endothelial cell (PAEC) [1]. Indeed, a large body of works has shown that damaged or apoptotic PAECs initiate the remodelling process through the release of growth, fibrogenic and pro-inflammatory factors that directly induce contraction and enhance survival and proliferation of adjacent PA smooth muscle cells (PASMCs) and fibroblasts [1, 2]. Over the past decade, intense research efforts have been directed at deciphering how PH cells acquire their “cancer-like” properties. As a consequence, the therapeutic potential of numerous anti-neoplastic drugs have been tested in preclinical models with some of them reaching clinical assays [3]. Considering the biphasic pattern of apoptosis that characterises the disease ( i.e. PAEC apoptosis that triggers the disease is followed by an apoptosis-resistant state allowing vascular remodelling [4]), it is not surprising that some anticancer agents can both predispose to and treat pulmonary arterial hypertension (PAH). This is exemplified by studies showing that Dasatinib, a second-generation tyrosine kinase inhibitor (TKI) approved for Philadelphia chromosome positive chronic myeloid leukemia, improves established PAH in multiple animal models [5], while its administration before exposure to PH inducers exacerbates pulmonary vascular remodelling and PA pressures; histological and hemodynamic changes not observed in rats exposed to Dasatinib alone [6]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: Dr. Awada has nothing to disclose. Conflict of interest: Dr. GROBS has nothing to disclose. Conflict of interest: Dr. Wu has nothing to disclose. Conflict of interest: Dr. HABBOUT has nothing to disclose. Conflict of interest: Dr. Romanet has nothing to disclose. Conflict of interest: Dr. BREUILS-BONNET has nothing to disclose. Conflict of interest: Dr. TREMBLAY has nothing to disclose. Conflict of interest: Dr. Martineau has nothing to disclose. Conflict of interest: Dr. Paulin has nothing to disclose. Conflict of interest: Dr. BONNET has nothing to disclose. Conflict of interest: Dr. Provencher has nothing to disclose. Conflict of interest: Dr. POTUS has nothing to disclose. Conflict of interest: Dr. BOUCHERAT has nothing to disclose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|